HomeAnswersHematologymultiple myelomaWill allogeneic transplantation help multiple myeloma?

My mother is having mutiple myeloma. Will allogeneic transplantation help her?

Share

The following is an actual conversation between an iCliniq user and a doctor that has been reviewed and published as a Premium Q&A.

Answered by

Dr. Singh Smrita

Medically reviewed by

iCliniq medical review team

Published At February 25, 2018
Reviewed AtAugust 16, 2023

Patient's Query

Hi doctor,

Recently, my mother is diagnosed with multiple myeloma. She had a fast progression. Within a year, the plasmacytoma progressed to MGUS which resulted in multiple myeloma with severe bone involvement. She got a heart attack at the onset of multiple myeloma. I know that deletion of 17p and mutations of TP53 are associated with a poor prognosis.

My mother has not undergone cytogenetic testing. My two sons carry a germline (not somatic) deletion of seven genes on 17p13.2. This deletion does not include TP53, but it includes MYBBP1A which is known to regulate TP53 and deletion. It is implicated in some cancers. If my mother has this deletion, what will be her treatment? She is getting the ideal treatment for 17p deletion. She takes Velcade, Revlimid, and Dex with Zometa. Germline mutation makes an autologous transplant less likely to help. Can allogeneic transplantation help her? What does a germline mutation mean?

Answered by Dr. Singh Smrita

Hi,

Welcome to icliniq.com.

The advantage of allogeneic stem cell transplant is that the donor stem cells make their immune cells. They help to destroy the cancer cells that remain after high-dose treatment. It is called a graft-versus-cancer effect. Autologous stem cell transplant does not offer the benefits of the graft versus tumor (GVL) effect when healthy donor cells attack cancer cells, and they do not carry the risk of transplantation rejection due to graft versus host reaction.

They are relatively safe procedures, with low rates of complications and infections compared with allogeneic transplants. Deaths due to the transplant are approximately 2 % to 3 % in patients with newly diagnosed myeloma. In theory, one disadvantage of autologous stem cell transplant is that the transplant can potentially get contaminated with tumor cells when patient stem cells are used. However, recent studies indicate that this is not a significant problem and it is not a significant cause of myeloma relapse.

Same symptoms don't mean you have the same problem. Consult a doctor now!

Dr. Singh Smrita
Dr. Singh Smrita

Hematology

Community Banner Mobile
By subscribing, I agree to iCliniq's Terms & Privacy Policy.

Ask your health query to a doctor online

Hematology

*guaranteed answer within 4 hours

Disclaimer: No content published on this website is intended to be a substitute for professional medical diagnosis, advice or treatment by a trained physician. Seek advice from your physician or other qualified healthcare providers with questions you may have regarding your symptoms and medical condition for a complete medical diagnosis. Do not delay or disregard seeking professional medical advice because of something you have read on this website. Read our Editorial Process to know how we create content for health articles and queries.

This website uses cookies to ensure you get the best experience on our website. iCliniq privacy policy